Abivax Stock Surges 30% on New Bowel Drug Data

Shares of French biotech firm Abivax jumped 30% on Tuesday. The surge followed the release of new clinical data for its lead experimental drug, which targets chronic bowel disease. Investors reacted positively to the results, though the medicine remains in development and requires further regulatory approval.